What side effects are associated with this type of intervention?

The most common treatments for Idiopathic CD4 Lymphopenia (ICL) that aim to increase CD4 T cell counts, such as NT-17, may include side effects like injection site reactions, flu-like symptoms, and potential immune system overactivation leading to autoimmune conditions. Other treatments for immune deficiencies often carry risks of infections, infusion reactions, and general immunosuppressive effects. It is important to monitor patients closely for these side effects during treatment.

What prior FDA approvals exist?

There are currently no FDA-approved treatments specifically targeting the underlying deficiency of CD4 T cells in Idiopathic CD4 Lymphopenia (ICL). The trial of NT-17 (Efineptakin Alfa) is investigating a novel approach to increase CD4 T cell counts in ICL patients, which is a unique strategy as existing treatments focus on managing infections and associated conditions rather than addressing the CD4 T cell deficiency itself.

What other types of research exist?

Currently, there are no specific alternatives to NT-17 mentioned for increasing CD4 T cell counts in Idiopathic CD4 Lymphopenia patients. However, exploring other immunomodulatory treatments, such as monoclonal antibodies targeting immune pathways or cytokine therapies, might provide potential alternatives. Consulting with a healthcare provider for the latest research and clinical trials in 2024 is recommended.

← Back to Search

Cytokine

NT-I7 for Idiopathic CD4 Lymphopenia

Phase 1 & 2

Waitlist Available

Led By Andrea Lisco, M.D.

Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 60

Awards & highlights

Study Summary

This trial tests a new drug (NT-17) to increase the number of CD4 T cells in people with Idiopathic CD4 Lymphopenia (ICL), ages 18-75, enrolled in NIH protocol. Includes physical exams, blood tests, lumbar puncture & 3 doses of NT-17. Follow-up visits every 3 months.

Who is the study for?

Adults aged 18-75 with Idiopathic CD4 Lymphopenia (ICL), a condition where they have dangerously low levels of certain immune cells, can join this trial. They must be part of another NIH study and not pregnant or breastfeeding. People with HIV, hepatitis B/C, other immunodeficiencies, recent cancer treatments, severe illnesses, or using certain medications are excluded.Check my eligibility

What is being tested?

The trial is testing NT-I7 (Efineptakin Alfa), a new drug designed to increase CD4 T cell counts in people with ICL. Participants will receive three doses via injection over several months and undergo regular blood tests, leukapheresis procedures to collect white blood cells, and possibly additional exams like lumbar punctures.See study design

What are the potential side effects?

Potential side effects may include discomfort at the injection site, reactions related to the immune system's response such as fever or fatigue due to increased activity of white blood cells. More specific side effects will be monitored throughout the trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 60

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 60

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 60 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number and severity of AEs possibly, probably, or definitely related to NT I7 administration evaluated at week 60 (end-of-study visit).

Secondary outcome measures

CD4 Antigens

Trial Design

1Treatment groups

Experimental Treatment

Group I: Single CohortExperimental Treatment1 Intervention

Patients with ICL who are enrolled in 09-I-0102.

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Treatments for Idiopathic CD4 Lymphopenia (ICL) that aim to increase CD4 T cell counts, such as NT-17, work by enhancing the proliferation and survival of these crucial immune cells. NT-17 is a long-acting recombinant human IL-7, a cytokine essential for T cell development. By boosting CD4 T cell levels, these treatments address the core deficiency in ICL, potentially reducing the risk of severe infections, autoimmune diseases, and cancers, thereby improving patient outcomes.

Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab.

Find a Location

Who is running the clinical trial?

NeoImmune TechUNKNOWN

3 Previous Clinical Trials

182 Total Patients Enrolled

National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor

3,277 Previous Clinical Trials

5,487,393 Total Patients Enrolled

1 Trials studying Idiopathic CD4 Lymphopenia

20 Patients Enrolled for Idiopathic CD4 Lymphopenia

Andrea Lisco, M.D.Principal InvestigatorNational Institute of Allergy and Infectious Diseases (NIAID)

2 Previous Clinical Trials

950 Total Patients Enrolled

Media Library

Recombinant human interleukin (IL) 7-hyFc (Cytokine) Clinical Trial Eligibility Overview. Trial Name: NCT05600920 — Phase 1 & 2

Idiopathic CD4 Lymphopenia Research Study Groups: Single Cohort

Idiopathic CD4 Lymphopenia Clinical Trial 2023: Recombinant human interleukin (IL) 7-hyFc Highlights & Side Effects. Trial Name: NCT05600920 — Phase 1 & 2

Recombinant human interleukin (IL) 7-hyFc (Cytokine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05600920 — Phase 1 & 2

~40 spots leftby Nov 2026

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.